B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
GRCE
Grace TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+66.0
Score
AI commentary
The scheduled August 6 post-earnings packet did not provide a new earnings release, consensus comparison, analyst reaction, or target revisions. The retrieved August 6 SEC filing was a financing update rather than operating results; the latest available quote near $2.13 is only modestly above the $2.12 anchor. Primary evidence is constructive on regulatory clarity but forward visibility remains weak, so this is a monitoring-style view.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-18eventFY2026 results show lower reported loss but remain pre-commercialMedium impact
Grace reported a FY2026 net loss of $7.8 million versus $9.6 million previously; R&D expense fell to $2.4 million largely after completion of the pivotal safety trial, while NDA-support costs continued. [#SEC-8K-2026-06-18] [#PR-EARNINGS-2026-06-18]
2026-08-06catalystPrivate placement extends runway but adds dilution pressureMedium impact
The August offering sold 4,761,904 shares at $2.10 and generated approximately $10 million gross proceeds before expenses. The capital is supportive, but the enlarged share count may cap near-term upside. [#SEC-8K-2026-08-06] [#8-K-2026-08-06]
2026-11-06eventRegulatory remediation and NDA resubmission pathHigh impact
Type A meeting minutes reportedly indicated no clinical safety or efficacy deficiency and no request for additional clinical data, but CMC, non-clinical, cGMP, and manufacturing remediation remain. No resubmission date is disclosed. [#SEC-8K-2026-07-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology